This study will test the hypothesis intracoronary administration of OmniMSC-AMI (allogenic bone marrow-derived mesenchymal stem cells) just after finishing the primary percutaneous coronary intervention (PCI) in ST-segment elevation myocardial infarction (STEMI) patients without cardiogenic shock is safe and may provide benefit on improving left ventricular ejection fraction (LVEF) during clinical follow-up.
Patents, with age ≤20 or ≤80 years old.
Chest pain onset.
12-lead EKG:V1-V6 ≥ consecutive lead ST-segment elevation ≥1 mm.
TnT-I elevation.
Age < 20 or >80 years old.
History of
Malignancy.
Sepsis (abnormal WBC count elevation).